Association of Serum Levels of Ustekinumab, Vedolizumab, and Faecal Calprotectin in Paediatric Patients with Inflammatory Bowel Diseases: A Prospective Observational Study.

For VEDO we added analysis of the disease extension, where E1/E2 versus E3/E4 reached borderline significance when added to the linear mixed model being positively associated with higher F-CPT ( β 1.915, 95% CI 0.1696–3.6621, p = 0.045).

also in 91 other papers